Synteract talks rescue studies at DIA 2011

By Gareth Macdonald

- Last updated on GMT

Synteract says the use of non-validated data systems in clinical trials is a key driver for the ‘rescue study’ segment of the contract research sector.

COO Stewart Bieler made the comments during an interview with Outsourcing-pharma.com at DIA 2011. He explained that Synteract is sometimes called to ‘rescue’ a study when a non-CFR Part 11​validated system is used.

He explained that when called in to rescue a study Synteract first assesses the programme's complexity to determine if it is feasible to take over.

Bieler also said that, in terms of disease areas, over 30 per cent of the trials Synteract takes over are those involved in the development of cancer drugs.

Oncology trials Outsourcing

Oncology is one of the most active areas of research in the pharmaceutical industry with, according to recent PhRMA figures, more than 900 new cancer drugs being developed by US companies alone.

The contract research sector has been quick to recognise this demand with barely a week going by without news of a cancer trial partnership or new oncology-focused service launch.

With this trend in mind, on July 12th Outsourcing-pharma.com is holdingOncology Trials Outsourcing​an industry-first virtual conference focused on the role outsourcing can play in the successful development of cancer drugs.

Experts from​Cutting Edge Information, INC Research, Quintiles​and​Eli Lilly​will lead our webinar programme, sharing their thoughts on the important issues and instantly fielding questions from you, our online audience.

Sign up to "attend" our innovative, online only event for freehere​.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars